STOCK TITAN

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Ocular Therapeutix (OCUL) granted equity awards to Tiffany Howard, its new Executive Vice President, Commercial – Retina, effective November 16, 2026. The awards were an inducement for Howard to accept employment and were granted under the 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Howard received a ten-year option to buy up to 200,000 common shares at $6.01 per share, the closing price on the grant date, and restricted stock units covering 65,000 common shares. The option vests over four years and the units over three, both subject to continued service through the applicable vesting dates.

Loading...
Loading translation...

Positive

  • None.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Ten-year stock option could dilute shareholders by up to 200,000 common shares if exercised at $6.01 per share
  • Minor point. Forward-looking: it has not happened yet and may not happen.Restricted stock units could dilute shareholders by 65,000 common shares, with vesting over three years subject to continued service

Key Figures

Stock options: up to 200,000 shares Restricted stock units: 65,000 shares Option exercise price: $6.01 per share +3 more
Stock options
up to 200,000 shares
Inducement award
Restricted stock units
65,000 shares
Inducement award
Option exercise price
$6.01 per share
Equal to the closing price on the grant’s effective date
Option term
ten years
Stock option award
Option vesting
over four years
25% vests on the first anniversary; the remainder vests in equal monthly installments over the next three years
RSU vesting
over three years
Equal annual installments on the first, second and third grant anniversaries

Historical Context

2 past events · Latest: Nov 06
2 events
  1. Nov 06

    Inducement grants

    24h Move
    +2.6%

    Eight new employees received stock options and restricted stock units under the inducement plan.

  2. Oct 09

    Inducement grants

    24h Move
    +0.4%

    Fifteen new employees received stock options and restricted stock units under the inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-statutory stock option, restricted stock unit, nasdaq listing rule 5635(c)(4)
3 terms
non-statutory stock option financial
"a non-statutory stock option award to purchase up to 200,000 shares"
A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.
restricted stock unit financial
"a restricted stock unit award representing the right to receive 65,000 shares"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
nasdaq listing rule 5635(c)(4) regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BEDFORD, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Tiffany Howard, the Company’s new Executive Vice President, Commercial – Retina. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of November 16, 2026, and consist of a non-statutory stock option award to purchase up to 200,000 shares of Ocular’s common stock and a restricted stock unit award representing the right to receive 65,000 shares of Ocular’s common stock. The stock option award has an exercise price of $6.01 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. The stock option award has a ten-year term and vests over four years, with 25% of the original number of shares subject to the award vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The restricted stock unit award vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Ocular Therapeutix grant Tiffany Howard?

Ocular Therapeutix granted Howard an option to buy up to 200,000 common shares at $6.01 per share and restricted stock units covering 65,000 common shares, effective November 16, 2026.

When do Tiffany Howard’s Ocular Therapeutix inducement awards vest?

The option vests 25% on the first grant anniversary, then monthly in equal installments over three years. The restricted stock units vest in equal installments on the first, second and third grant anniversaries. Both awards require continued service through the applicable vesting dates.

Keep reading